XRTX XORTX Corp: Net earnings per share for the last 12 months

XORTX Therapeutics Inc. (XRTX) focuses on the therapy of rare renal pathologies by blocking uric acid synthesis. The current YoY TTM growth in net income per share demonstrates capital dynamics, where 2.60 determines the current value of the metric. Growth is driven by venture investments and the success of new inhibitors, while the high safety profile of the molecules ensures the brand's trust among specialized professionals.
Financial and market metric breakdowns for XORTX Therapeutics (XRTX)

XORTX Therapeutics Inc. (XRTX) maintains a strong position in nephrology due to the safety of its molecules. The EPS YoY TTM trend measures the daily change in net profit per share over a year, revealing the actual growth rate of the business. Analyzing historical EPS YoY TTM dynamics allows for the separation of market expectations from actual returns. For this pharmaceutical company, this trend confirms the effectiveness of commercializing its developments. Stable growth of this indicator signals the fundamental resilience of the asset.